Phase I/II trial of subcutaneous IL-2 [interleukin-2] with highly active antiretroviral therapy in HIV-infected children with immunosuppression.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Aldesleukin; Antiretrovirals; Diphtheria-tetanus vaccine; Interleukin-2; Phi X 174
- Indications HIV infections
- Focus Adverse reactions
- 21 May 2012 Biomarkers information updated
- 11 May 2012 Planned number of patients changed from 84 to 92 as reported by ClinicalTrials.gov.
- 11 May 2012 Investigational drugs identified as reported by ClinicalTrials.gov.